Key result
Provisional main branch stenting with POT is the recommended default approach for BRS bifurcation lesions.
Why the study?
Does the use of bioresorbable coronary scaffolds (BRS) improve outcomes compared to metallic DES in patients with bifurcation lesions?
Does the use of bioresorbable coronary scaffolds (BRS) improve outcomes compared to metallic DES in patients with bifurcation lesions?
This review discusses bench testing and early clinical data regarding the potential advantages and inherent limitations of using bioresorbable coronary scaffolds in bifurcation lesions.
Answers are grounded in this paper and cite their sources.
Supports provisional BRS bifurcation technique with early data; leaves open superiority versus metallic DES.
Bioresorbable coronary scaffolds (BRS) may offer potential advantages compared to metallic DES, aiming to restore vessel patency without implanting a permanent prosthesis, which may be especially important for bifurcation treatment. On the other hand, there are some inherent limitations, which may impact on the widespread use of BRS. In the current article we discuss the bench testing data and initial clinical results on BRS use in bifurcation lesions presented during European Bifurcation Club (EBC) meetings and review some of the limited number of published real-world registry results.
No takes yet. Share an insight, caveat, or question.
Stanković et al. (2015) conducted a review in Coronary bifurcation lesions. Bioresorbable coronary scaffolds (BRS) vs. Metallic drug-eluting stents (DES) was evaluated. A provisional strategy with main branch stenting followed by the proximal optimization technique (POT) is the recommended default approach for treating coronary bifurcation lesions with bioresorbable scaffolds.
Synapse has enriched 10 related papers. Consider them for comparative context: